Delivery Order SPE2DB22D2206-SPE2DB25FKD58
- Not listed
- The Defense Logistics Agency awarded a $9,584.58 delivery order to AmerisourceBergen Drug Corp for the supply of Trodelvy 180 mg vials, with a completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order reflects the pharmaceutical distributor's ongoing role as a critical medical supplier to federal healthcare systems. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $9,584.58 to supply Trodelvy 180 mg vials, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order was issued on August 5, 2025, with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location in...
- The Defense Logistics Agency's Medical Supply Chain has awarded a delivery order valued at $22,364.02 to AmerisourceBergen Drug Corp for the supply of Trodelvy 180 mg vials. This competitively awarded, firm fixed-price contract is scheduled for completion by October 14, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. No set-aside designation was utilized for this procurement. This delivery order is executed under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $22,364.02 delivery order to AmerisourceBergen Drug Corp for 180 mg vials of Trodelvy, a pharmaceutical product for medical supply distribution. This competitively awarded, non-set-aside contract operates under firm fixed pricing with a completion deadline of October 21, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 23, 2025, by the Defense Logistics Agency (DLA) to supply 180 mg vials of Trodelvy, a specialty pharmaceutical product used in oncology treatment. The order, valued at $19,169.16 with a firm fixed price structure, is scheduled for completion by October 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive, non-set-aside award...
- The Defense Logistics Agency awarded a $6,389.72 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Trodelvy 180 mg vials, with an ultimate completion date of August 25, 2025. This non-set-aside competitive award represents a single delivery order issued under AmerisourceBergen's larger pharmaceutical supply contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order valued at $9,584.58 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Trodelvy 180 mg vials, with a completion deadline of September 5, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor's corporate office located in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader relationship with the federal...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Trodelvy 180 mg vials, a specialty pharmaceutical product. This competitively awarded, firm fixed-price delivery order has a ceiling value of $9,584.58 and is scheduled for completion by October 15, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and carries no set-aside designation. This...
- AmerisourceBergen Drug Corp was awarded a delivery order contract on September 22, 2025, by the Defense Logistics Agency Medical Supply Chain to supply one vial of Trodelvy 180mg, a oncology therapeutic medication, for delivery to Conshohocken, Pennsylvania. The contract is a firm fixed price delivery order with a ceiling value of $19,169.16 and an ultimate completion date of September 23, 2025. No set-aside designation was applied to this competitive award, demonstrating AmerisourceBergen's...
- The Defense Logistics Agency's Medical Supply Chain awarded a $9,584.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Trodelvy 180 mg vials, with an ultimate completion date of August 18, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC SPE2DX) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026....
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKD58Delivery Order
The Defense Logistics Agency awarded a $15,974.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 180 mg vials of Trodelvy, a specialty pharmaceutical product. The award was made competitively with no set-aside designation and carries an ultimate completion date of October 20, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location in the same municipality. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen's federal contract portfolio demonstrates extensive capability in delivering both brand-name and generic medications, vaccines, and specialized healthcare commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.0k | 9/28/25 |